Table 2. Agents Used for Type II HIT
Agent | Lepirudin | Argatroban | Danaparoid* |
---|---|---|---|
Brand Name | Refludan® | Argatroban® | Orgaran® |
Mechanism | Direct thrombin inhibitor | Direct thrombin inhibitor | Accelerates activity of antithrombin III against factor Xa and factor IIa |
Dosing | 0.4
mg/kg IV bolus followed by infusion of 0.15 mg/kg/hour NOTE: Dose adjustment required in renal insufficiency | Start at
2 mcg/kg/min Dosing can be increased up to a maximum of 10 mcg/kg/min NOTE: Dose adjustment required in hepatic insufficiency |
2500 U bolus followed by infusion of 400 U/hour for 4 hours, then 300 U/hour for 4 hours, then maintenance of 150-200 U/hour |
Monitoring | aPTT | aPTT Transition to warfarin: At dose of 2 mcg/kg/min Discontinue infusion, check INR after 4 to 6 hours after infusion stopped At dose of >2 mcg/kg/min Titrate infusion to 2 mcg/kg/min, check INR after 4 to 6 hours while at 2 mcg/kg/min |
Anti-Xa
activity monitoring recommended in patients with renal impairment and inpatients
<55 and >90 kg |
Half-life | 40 to 120 minutes | 24 to 50 minutes | 18 to 28 hours |
Reversal agent | None | None | None |
* NOT FDA-approved for Type II HIT.
Click Here to Return to Article